Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies-Reference-Cited by-同舟云学术

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies

Published:2017-10-12 Issue:2 Volume:124 Page:297-305
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sloot Sarah¹²,Chen Yian A.³,Zhao Xiuhua³,Weber Jamie L.⁴,Benedict Jacob J.⁴,Mulé James J.⁵,Smalley Keiran S.²⁶,Weber Jeffrey S.⁷,Zager Jonathan S.²⁸⁹,Forsyth Peter A.¹⁰¹¹,Sondak Vernon K.²⁸⁹,Gibney Geoffrey T.¹²

Affiliation:

1. Department of General Surgery; Groningen University Medical Center; Groningen The Netherlands

2. Department of Cutaneous Oncology; Moffitt Cancer Center; Tampa Florida

3. Department of Biostatistics and Bioinformatics; Moffitt Cancer Center; Tampa Florida

4. Morsani College of Medicine; University of South Florida; Tampa Florida

5. Department of Immunology; Moffitt Cancer Center; Tampa Florida

6. Department of Tumor Biology; Moffitt Cancer Center; Tampa Florida

7. Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center; New York New York

8. Department of Oncologic Sciences, Morsani College of Medicine; University of South Florida; Tampa Florida

9. Department of Surgery, Morsani College of Medicine; University of South Florida; Tampa Florida

10. Department of Neurooncology; Moffitt Cancer Center; Tampa Florida

11. Department of Neurooncology; Southern Alberta Cancer Research Institute; Calgary Alberta Canada

12. Georgetown Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital; Washington DC

Funder

SPORE

Melanoma Sarcoma Groningana Foundation

NIH Clinical Center

Mirati Therapeutics and Acetylon Pharmaceuticals

Amgen, Delcath Systems, Provectus, and Castle Biosciences

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference40 articles.

1. Prognostic factors for survival in melanoma patients with brain metastases;Davies;Cancer,2011

2. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma;Sampson;J Neurosurg,1998

3. Diagnosis and treatment of melanoma brain metastasis: a literature review;Sloan;Cancer Control,2009

4. Determinants of outcome in melanoma patients with cerebral metastases;Fife;J Clin Oncol,2004

5. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival;Zakrzewski;Cancer,2011

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Non-Overlapping Somatic Mutations in BRAF, NRAS, NF1, or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma;Cancers;2024-01-30

2. Molecular dynamics exploration of Lupenone: therapeutic implications for glioblastoma multiforme and alzheimer's amyloid beta pathogenesis;Metabolic Brain Disease;2023-12-22

3. Predicting the BRAF mutation with pretreatment MRI radiomics features for melanoma brain metastases receiving Gamma Knife radiosurgery;Clinical Radiology;2023-12

4. Acquired and intrinsic resistance to vemurafenib in BRAF^V600E‐driven melanoma brain metastases;FEBS Open Bio;2023-11-30

5. Outcomes Following Early Postoperative Adjuvant Radiosurgery for Brain Metastases;JAMA Network Open;2023-10-31